Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 10/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | FADS1 | O60427 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616394 | 1.00 | PFKFB3 (0.46) | PFKFB3GBA1PDPK1ALDH1A1CYP1A2 | |
| SCHEMBL1616241 | 0.87 | GBA1 (0.50) | PFKFB3GBA1PDPK1ALDH1A1CYP3A4 | |
| SCHEMBL1616249 | 0.87 | GBA1 (0.50) | PFKFB3GBA1PDPK1ALDH1A1CYP3A4 | |
| SCHEMBL1616160 | 0.86 | PFKFB3 (0.46) | PFKFB3GBA1PDPK1ALDH1A1CYP3A4 | |
| SCHEMBL2245619 | 0.83 | GBA1 (0.47) | PFKFB3GBA1PDPK1FADS1EGFR | |
| SCHEMBL1616137 | 0.83 | PFKFB3 (0.42) | PFKFB3GBA1PDPK1FADS1EGFR | |
| SCHEMBL1616136 | 0.83 | PFKFB3 (0.42) | PFKFB3GBA1PDPK1FADS1EGFR | |
| SCHEMBL1616633 | 0.83 | HDAC6 (0.43) | PFKFB3GBA1PDPK1FADS1HDAC6 | |
| SCHEMBL1616631 | 0.83 | HDAC6 (0.43) | PFKFB3GBA1PDPK1FADS1HDAC6 | |
| SCHEMBL3844986 | 0.81 | PDPK1 (0.47) | PFKFB3GBA1PDPK1FADS1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099763-B1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | claimed |
| US-7923561-B2 | Quinolines | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2099763-B1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-20080146567-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146567-A1 | QUINOLINES | HTR5A, HTR2B, HTR2C | PFKFB3 4177/4885GBA1 662/4885PDPK1 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.